Global Capecitabine Market to Reach USD 2,022.18 Million by 2030 | CAGR of 4.8%
Category : Healthcare | Published Date : Nov 2024 | Type : Press Release
Capecitabine Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Global Capecitabine Market size was valued at USD 1,020.00 million in 2022 and is projected to register a CAGR of 5.5%, reaching USD 1,558.74 million by 2030. Capecitabine is an anticancer medication utilized for treating various types of cancers, including colorectal cancer, breast cancer, and gastric cancer. It works by interfering with the growth of cancer cells and is often used in combination with other cancer treatments.
The report comprises the Capecitabine Market Share, Size & Industry Analysis, By Form (Tablets, Powder), By Indication (Breast Cancer, Colorectal Cancer, Gastric Cancer, Others), By End-User (Hospitals, Specialty Clinics, Homecare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2023-2030.
The report contains detailed information on Capecitabine Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints, PESTLE Analysis, PORTER Analysis, and Cost Analysis.
Rising prevalence of cancer cases globally is driving the demand for capecitabine, while ongoing research into innovative formulations presents further opportunities for market growth.
Segmental Analysis :
By Form:
- Tablets accounted for the largest market share in 2022, favored for their ease of use, precision in dosage, and convenient packaging, which supports patient adherence to cancer treatment protocols.
- Powder is projected to witness the fastest growth, driven by increasing research and development activities focused on enhancing the adoption of capecitabine powder formulations.
By Indication:
- Breast Cancer was the leading segment in 2022, as capecitabine is widely used for treating advanced and metastatic breast cancer cases, especially in patients who are resistant to other chemotherapy drugs.
- Colorectal Cancer is expected to grow significantly due to its effectiveness as a first-line therapy in combination with other anticancer agents, offering a targeted approach for improved patient outcomes.
By End-User:
- Hospitals held the highest market share in 2022, attributed to the availability of comprehensive cancer care services and the widespread use of capecitabine in chemotherapy protocols.
- Specialty Clinics are expected to register the fastest growth, supported by increasing investments in new clinic facilities and enhanced access to cancer-specific treatments.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
- North America dominated the market in 2022, driven by the high prevalence of cancer and the extensive availability of capecitabine treatments across healthcare facilities.
- Asia-Pacific is anticipated to grow at the highest CAGR, supported by rising healthcare expenditures and advancements in cancer treatment options in countries like China and India.
| Report Attributes | Report Details |
| Study Timeline | 2017-2030 |
| Market Size in 2030 | USD 1,558.74 Million |
| CAGR (2023-2030) | 5.5% |
| By Form | Tablets, Powder |
| By Indication | Breast Cancer, Colorectal Cancer, Gastric Cancer, Others |
| By End-User | Hospitals, Specialty Clinics, Homecare, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape includes key pharmaceutical companies specializing in cancer treatments. These players are actively engaged in research and development activities and expanding their product portfolios. The report features detailed profiles, market share analysis, and emerging trends.
List of prominent players in the Capecitabine Industry:
- Teva Pharmaceuticals, Inc
- F. Hoffmann-La Roche AG
- Mylan N.V.
- Hikma Pharmaceuticals PLC
- Cipla Inc.
- Dr. Reddy's Laboratories Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Limited
- Genentech, Inc.
- Accord Healthcare Ltd.
Recent Industry Developments :
- February 2021: Dr. Reddy's Laboratories launched a generic version of Xeloda (capecitabine) tablets in the U.S. market, expanding their product offerings in oncology.
